TAMPA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
(RTTNews) - Pacira BioSciences, Inc. (PCRX) announced Wednesday positive topline results from its Phase 3 study of EXPAREL as a single-dose sciatic nerve block in the popliteal fossa for postsurgical ...
FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...
In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
Patients who received sciatic nerve block or local infiltration of analgesia as adjuncts to combined one-shot and continuous femoral nerve block experienced similar effects regarding the relief of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback